Peroxisomal acyl-CoA oxidase deficiency
per-ox-ee-so-mal a-sil ko-A ox-i-dase de-fi-cien-cy
Also known as: Pseudo-neonatal adrenoleukodystrophy, ACOX1 deficiency
At a Glance
What is Peroxisomal acyl-CoA oxidase deficiency?
Peroxisomal acyl-CoA oxidase deficiency is a rare genetic disorder that affects the body's ability to break down certain fats. This condition primarily impacts the nervous system and liver. It is caused by mutations in the ACOX1 gene, which leads to a deficiency in the enzyme acyl-CoA oxidase. Over time, the accumulation of very long-chain fatty acids can cause damage to the brain and liver. Early symptoms often include hypotonia, seizures, and developmental delays. As the condition progresses, individuals may experience liver dysfunction and neurological deterioration. Early diagnosis is crucial to manage symptoms and slow disease progression. The disorder can place a significant emotional and financial burden on families. Prognosis varies, but many affected individuals have a reduced life expectancy. Daily life for those affected may involve frequent medical visits and supportive therapies. Management focuses on symptomatic relief and supportive care. Genetic counseling is recommended for families with a history of the disorder.
Medical Definition
Peroxisomal acyl-CoA oxidase deficiency is a peroxisomal biogenesis disorder characterized by the accumulation of very long-chain fatty acids due to a defect in the ACOX1 gene. Pathologically, it results in demyelination and neuronal loss in the central nervous system, as well as hepatic steatosis. Histological findings may include peroxisomal abnormalities and liver fibrosis. It is classified under peroxisomal disorders and is part of the broader spectrum of leukodystrophies. Epidemiologically, it is an ultra-rare condition with an estimated prevalence of 1 in 1,000,000. The disease course is progressive, often leading to severe neurological impairment and early mortality.
Peroxisomal acyl-CoA oxidase deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hypotonia presents as decreased muscle tone and strength, often noticeable in infancy. It is caused by the accumulation of very long-chain fatty acids due to defective peroxisomal beta-oxidation. Over time, hypotonia can lead to developmental delays and difficulties in motor skills. Daily life is affected by challenges in mobility and coordination, and physical therapy can help improve muscle tone and function.
Developmental delay manifests as a significant lag in reaching developmental milestones such as sitting, walking, and talking. This occurs due to impaired neuronal function from disrupted fatty acid metabolism in the brain. As the child grows, the delay may become more pronounced, affecting learning and social interactions. Early intervention with specialized educational programs and therapies can support development.
Seizures in this condition can present as sudden, uncontrolled electrical disturbances in the brain. They result from neuronal instability caused by toxic accumulation of unmetabolized fatty acids. Seizures may increase in frequency and severity over time if not managed. Antiepileptic medications and regular neurological assessments are crucial for controlling seizures and improving quality of life.
Common
Hepatomegaly is characterized by an enlarged liver, often detected during physical examination. It is caused by the accumulation of lipids in liver cells due to defective peroxisomal function. Over time, this can lead to liver dysfunction and potential liver damage. Regular monitoring of liver function and dietary management can help mitigate the effects on the liver.
Vision problems may include impaired visual acuity and retinal degeneration. These issues arise from the accumulation of toxic metabolites affecting the optic nerve and retinal cells. As the condition progresses, vision may deteriorate, impacting daily activities such as reading and recognizing faces. Regular ophthalmologic evaluations and supportive visual aids can assist in managing these challenges.
Hearing loss can range from mild to severe and is often detected through audiometric testing. It results from the accumulation of toxic substances affecting the auditory pathways. Over time, hearing loss can hinder communication and language development. Hearing aids and speech therapy can be beneficial in improving communication skills.
Less Common
Adrenal insufficiency manifests as fatigue, weakness, and low blood pressure due to inadequate hormone production by the adrenal glands. This condition is linked to the accumulation of fatty acids interfering with adrenal function. If untreated, it can lead to an adrenal crisis, a life-threatening condition. Hormone replacement therapy and regular endocrinological assessments are essential for management.
Skin abnormalities may include dryness, scaling, and hyperpigmentation. These symptoms are due to the disruption of normal lipid metabolism affecting skin integrity. Over time, skin issues can lead to discomfort and increased susceptibility to infections. Topical treatments and maintaining good skin hygiene can help alleviate symptoms.
What Causes Peroxisomal acyl-CoA oxidase deficiency?
Peroxisomal acyl-CoA oxidase deficiency is primarily caused by mutations in the ACOX1 gene, located on chromosome 17q25.1. The ACOX1 gene encodes the enzyme acyl-CoA oxidase 1, which is crucial for the first step in the peroxisomal beta-oxidation of very-long-chain fatty acids (VLCFAs). Mutations in ACOX1 can lead to a truncated or misfolded protein, impairing its enzymatic activity. This results in the accumulation of VLCFAs within peroxisomes, disrupting normal lipid metabolism. The buildup of VLCFAs causes peroxisomal dysfunction, affecting the breakdown and synthesis of various lipids. Neighboring cells and tissues experience oxidative stress and lipid imbalance, contributing to cellular damage. Neuroinflammation is triggered as the immune system responds to cellular distress, exacerbating neural damage. White matter degeneration occurs due to the toxic effects of accumulated VLCFAs and inflammatory responses, leading to demyelination. Symptoms such as hypotonia, seizures, and developmental delay appear due to the progressive loss of neuronal function. The pattern of symptom onset is influenced by the specific mutation and residual enzyme activity. Disease severity varies between patients due to differences in mutation type, location, and the presence of modifier genes. Some patients may have partial enzyme activity, leading to milder phenotypes. Environmental factors and other genetic variations can also modulate disease progression. Understanding these mechanisms is crucial for developing targeted therapies. Early diagnosis and intervention can help manage symptoms and improve quality of life.
How is Peroxisomal acyl-CoA oxidase deficiency Diagnosed?
Typical age of diagnosis: Peroxisomal acyl-CoA oxidase deficiency is typically diagnosed in infancy or early childhood when symptoms such as developmental delay, hypotonia, and seizures become apparent. Diagnosis often follows the presentation of neurological symptoms and failure to thrive, prompting further investigation.
Clinicians look for developmental delays, hypotonia, and seizures in the patient's history. A detailed family history may reveal similar conditions or consanguinity. Physical examination often shows hypotonia and possible hepatomegaly. This step helps determine the need for further biochemical and genetic testing.
Magnetic Resonance Imaging (MRI) of the brain is commonly used. Specific abnormalities such as white matter changes and cerebral atrophy may be visible. These findings support the diagnosis of a peroxisomal disorder by correlating clinical symptoms with structural brain changes. Differential diagnoses such as other leukodystrophies are excluded based on imaging patterns.
Plasma very long-chain fatty acids (VLCFA) levels are measured. Elevated VLCFA levels are indicative of peroxisomal dysfunction. Abnormal results typically show increased C26:0 and C24:0/C22:0 ratios. These results guide the decision to proceed with genetic testing for confirmation.
The ACOX1 gene is sequenced to identify mutations. Mutations such as missense, nonsense, or large deletions are commonly found. Positive results confirm the diagnosis of peroxisomal acyl-CoA oxidase deficiency. Genetic results are crucial for family counseling and assessing recurrence risk.
Peroxisomal acyl-CoA oxidase deficiency Treatment Options
Lorenzo's Oil is a mixture of oleic and erucic acids. It works by competitively inhibiting the elongation of saturated VLCFAs. Clinical evidence suggests it may slow the progression of neurological symptoms. However, its efficacy is variable and it does not reverse existing damage. Side effects include gastrointestinal disturbances and potential liver dysfunction.
Techniques such as stretching, strengthening, and motor skill exercises are used. The goal is to improve muscle tone, coordination, and functional mobility. Sessions are typically held 2-3 times per week over several months. Measurable outcomes include improved motor milestones and reduced spasticity. Long-term benefits include enhanced quality of life and delayed progression of physical symptoms.
Indicated for patients with severe feeding difficulties and failure to thrive. The procedure involves placing a tube directly into the stomach for nutritional support. Expected benefits include improved nutritional status and growth. Surgical risks include infection and tube dislodgement. Post-operative care requires regular monitoring and tube maintenance.
The team includes neurologists, dietitians, physical therapists, and genetic counselors. Interventions focus on symptom management, nutritional support, and developmental therapies. Psychosocial support strategies involve counseling and support groups for families. Family education covers disease progression, care techniques, and genetic implications. Long-term monitoring includes regular assessments and adjustments to care plans.
When to See a Doctor for Peroxisomal acyl-CoA oxidase deficiency
- Severe seizures — indicate a critical neurological issue requiring immediate medical intervention.
- Sudden loss of consciousness — could signify a life-threatening metabolic crisis.
- Acute respiratory distress — indicates potential respiratory failure, necessitating emergency care.
- Progressive muscle weakness — may suggest advancing neurological impairment; consult a neurologist.
- Developmental delays — could indicate worsening of the condition; early intervention is crucial.
- Persistent vomiting — may lead to dehydration and requires medical evaluation.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional headaches — keep track of frequency and intensity, and consult if they worsen.
Peroxisomal acyl-CoA oxidase deficiency — Frequently Asked Questions
Is this condition hereditary?
Peroxisomal acyl-CoA oxidase deficiency is inherited in an autosomal recessive pattern. This means both parents must be carriers for a child to be affected. There is a 25% chance of passing the condition to offspring if both parents are carriers. De novo mutations are rare but possible. Genetic counseling is recommended for affected families to understand carrier status and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly with the age of onset; early-onset cases often have a poorer prognosis. Factors such as severity of neurological symptoms and respiratory complications can worsen outcomes. Mortality is often due to severe neurological deterioration or respiratory failure. Early diagnosis and supportive treatments can improve quality of life and potentially extend survival. Families should have realistic expectations and prepare for progressive care needs.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, biochemical tests, and genetic analysis. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as neurologists and geneticists are typically consulted. Delays in diagnosis are common due to symptom overlap with other conditions. Confirmation is achieved through genetic testing identifying mutations in the ACOX1 gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy being a promising area of study. Novel approaches aim to correct the underlying genetic defect or manage symptoms more effectively. Clinical trials can be found on ClinicalTrials.gov by searching for 'peroxisomal acyl-CoA oxidase deficiency.' Patients should discuss potential trial participation with their healthcare provider. New treatments may take years to become widely available, but ongoing research offers hope.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care, often requiring assistive devices. Educational support may be necessary due to cognitive and developmental challenges. Social and emotional difficulties are common, necessitating psychological support. The family burden can be substantial, with caregivers needing respite and support. Adaptations such as specialized education plans and home modifications can greatly assist daily living.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.[Peroxisomal acyl-CoA oxidase deficiency].
Suzuki Y · Ryoikibetsu Shokogun Shirizu · 1998 · PMID: 9645072
- 2.Peroxisomal acyl-CoA-oxidase deficiency: two new cases.
Carrozzo R, Bellini C, Lucioli S et al. · Am J Med Genet A · 2008 · PMID: 18536048
- 3.Peroxisomal acyl CoA oxidase deficiency.
Suzuki Y, Iai M, Kamei A et al. · J Pediatr · 2002 · PMID: 11815777
- 4.Novel ACOX1 mutations in two siblings with peroxisomal acyl-CoA oxidase deficiency.
Morita A, Enokizono T, Ohto T et al. · Brain Dev · 2021 · PMID: 33234382
- 5.Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy.
Fournier B, Saudubray JM, Benichou B et al. · J Clin Invest · 1994 · PMID: 8040306
- 6.Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency.
Ferdinandusse S, Denis S, Hogenhout EM et al. · Hum Mutat · 2007 · PMID: 17458872
- 7.Pristanic acid does not accumulate in peroxisomal acyl-CoA oxidase deficiency: evidence for a distinct peroxisomal pristanyl-CoA oxidase.
ten Brink HJ, Poll-The BT, Saudubray JM et al. · J Inherit Metab Dis · 1991 · PMID: 1779614
- 8.Novel subtype of peroxisomal acyl-CoA oxidase deficiency and bifunctional enzyme deficiency with detectable enzyme protein: identification by means of complementation analysis.
Suzuki Y, Shimozawa N, Yajima S et al. · Am J Hum Genet · 1994 · PMID: 8279468
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-06